Related Experiment Video
Updated: May 6, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Exploring novel MYH7 gene variants using in silico analyses in Korean patients with cardiomyopathy
Oc-Hee Kim1, Jihyun Kim1, Youngjun Kim1
1Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju, 28159, Republic of Korea.
Insights
This study identified MYH7 gene variants in Korean cardiomyopathy patients, including novel pathogenic variants. In silico analyses confirmed their potential to cause disease, aiding in improved diagnosis.
Area of Science:
- Genetics
- Cardiology
- Bioinformatics
Background:
- Pathogenic variants in the MYH7 gene are a significant cause of dilated and hypertrophic cardiomyopathy.
- MYH7 encodes the beta-myosin heavy chain protein, crucial for cardiac muscle function.
Purpose of the Study:
- To identify MYH7 gene variants in Korean patients with various cardiomyopathy subtypes.
- To predict the pathogenicity of novel MYH7 variants using in silico methods.
- To evaluate the functional and structural impact of identified MYH7 variants.
Main Methods:
- Whole-genome sequencing was performed on 397 patients.
- In silico analyses (SIFT, Mutation Assessor, etc.) were used to predict variant pathogenicity.
- Protein dynamics and stability were assessed using DynaMut2 and Missense3D tools.
Main Results:
- Twenty-seven MYH7 variants were identified in 41 patients, including 5 novel variants.
- Pathogenic variants were predominantly located in the myosin motor domain.
- In silico predictions and functional assessments indicated the novel variants are likely pathogenic.
Conclusions:
- This study characterizes MYH7 variant distribution in Korean cardiomyopathy patients.
- In silico tools and functional assessments enhance the understanding of novel variant pathogenicity.
- Findings offer insights for improved diagnostic strategies for cardiomyopathy.
Background:
Pathogenic variants of MYH7, which encodes the beta-myosin heavy chain protein, are major causes of dilated and hypertrophic cardiomyopathy.
Methods:
In this study, we used whole-genome sequencing data to identify MYH7 variants in 397 patients with various cardiomyopathy subtypes who were participating in the National Project of Bio Big Data pilot study in Korea. We also performed in silico analyses to predict the pathogenicity of the novel variants, comparing them to known pathogenic missense variants.
Results:
We identified 27 MYH7 variants in 41 unrelated patients with cardiomyopathy, consisting of 20 previously known pathogenic/likely pathogenic variants, 2 variants of uncertain significance, and 5 novel variants. Notably, the pathogenic variants predominantly clustered within the myosin motor domain of MYH7. We confirmed that the novel identified variants could be pathogenic, as indicated by high prediction scores in the in silico analyses, including SIFT, Mutation Assessor, PROVEAN, PolyPhen-2, CADD, REVEL, MetaLR, MetaRNN, and MetaSVM. Furthermore, we assessed their damaging effects on protein dynamics and stability using DynaMut2 and Missense3D tools.
Conclusions:
Overall, our study identified the distribution of MYH7 variants among patients with cardiomyopathy in Korea, offering new insights for improved diagnosis by enriching the data on the pathogenicity of novel variants using in silico tools and evaluating the function and structural stability of the MYH7 protein.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy